echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Financial and accounting supervision and disciplinary inspection and supervision are coordinated to resolutely rectify corruption in the pharmaceutical field

    Financial and accounting supervision and disciplinary inspection and supervision are coordinated to resolutely rectify corruption in the pharmaceutical field

    • Last Update: 2021-07-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network April 15 hearing19 Jia illegal pharmaceutical companies be punished accounting supervision and discipline inspection and supervision collaborative development effortto prove safety of pharmaceutical companies with gold salesfor the ills of the masses to hold down prices reflect long-term, the authorities re-shot
    .
    On April 12, the Ministry of Finance issued an accounting information quality inspection announcement, imposing administrative penalties on 19 pharmaceutical companies, of which 2 were A-share listed companies, and Hengrui Pharmaceuticals once ranked first in the market value of the pharmaceutical sector
    .
    What is the root cause of the falsely high drug prices? How to resolve it? How to better play the role of financial and accounting supervision? Pharmaceutical companies tried their best to obtain funds, "pumping up" high sales and promotion expenses, and stuffing them into the pockets of medical agents.
    On the afternoon of April 12, the first joint law enforcement "success" of the Ministry of Finance and the National Medical Insurance Bureau began to show
    .
    Liu Feng, the second-level inspector of the Bureau of Supervision and Evaluation of the Ministry of Finance, concluded from three aspects: “After inspection, we have found out the cause of the falsely high drug prices, deterred the illegal behavior of pharmaceutical companies to sell money and drive up prices, and ensure the drug concentration belt.
    The smooth advancement of major reforms such as volume procurement
    .
    " "Sale with gold" refers to the improper behavior of pharmaceutical companies to seek trading opportunities or competitive advantages by giving rebates to prescribing doctors and people with decision-making power and influence on medicines
    .
    This part of the "cost" of commercial bribery will naturally be included in the calculation of pharmaceutical companies' bidding prices for drugs
    .
    Among the fined companies, the listed companies Hengrui Pharmaceuticals and Buchang Pharmaceuticals were directly named, and four companies under the listed company Shanghai Pharmaceuticals and one company each under China Resources Sanjiu and Fosun Pharma were notified
    .
    In addition, the subsidiaries of the global pharmaceutical giant Sanofi of France and Merck of Germany have been punished, and the subsidiaries of the multinational pharmaceutical company Eli Lilly have also been involved..
    Among the 19 pharmaceutical companies that were fined, there were three of them with a violation amount of over 100 million yuan, followed by Shenzhen China Resources Sanjiu Pharmaceutical Trading Co.
    , Ltd.
    , a subsidiary of China Resources Sanjiu, which exceeded RMB 164 million, Jiangsu Haosen Pharmaceutical Group Co.
    , Ltd.
    Marketing Co.
    , Ltd.
    140 million yuan
    .
    Article 9 of the "Accounting Law of the People's Republic of China" expressly stipulates: "All units must conduct accounting calculations based on actual economic and business matters, fill in accounting vouchers, register accounting books, and prepare financial accounting reports
    .
    No unit shall use false economic business Matters or data are accounted for
    .
    ” The problem of fined pharmaceutical companies is basically a violation of this regulation
    .
    The reporter combed through the administrative penalties announced by the Ministry of Finance and found that the problems were mainly concentrated in the following categories: First, the use of false invoices and bill arbitrage to obtain funds for external use
    .
    For example, Beijing Cheng Nuo Mei Di Technology Co.
    , Ltd.
    used the air tickets and invoices of unrelated personnel to offset the reimbursement and set up funds, involving an amount of 915,100 yuan
    .
    Tonghua Yusheng Pharmaceutical Co.
    , Ltd.
    listed false invoices for business promotion expenses, involving an amount of 1.
    7 million yuan
    .
    The second is to arbitrage funds for fictitious business matters
    .
    Fictitious business matters are concentrated in academic seminars, experience exchanges, market research, consulting, etc.
    , but they are often full of loopholes
    .
    For example, in 2018, Sanofi (Beijing) Pharmaceutical Co.
    , Ltd.
    listed 149 million yuan for academic seminars or experience exchange conferences in the medical field.
    The relevant doctors "participating" said that the meeting was untrue or did not participate in the meeting, and the amount involved was 938,200 yuan
    .
    The third is other accounting problems such as the irregular setting of account books
    .
    For example, Eli Lilly (Shanghai) Management Co.
    , Ltd.
    uses electronic computers for accounting and fails to set up general ledgers, subsidiary ledgers and other accounting books in accordance with the provisions of the national unified accounting system
    .
    Pharmaceutical companies have tried their best to use the pharmaceutical promotion company to extract funds, and "reversely" incur high sales and promotion expenses, just to be able to squeeze into the pockets of pharmaceutical agents
    .
    For example, Jiangsu Wanbang Pharmaceutical Marketing Co.
    , Ltd.
    paid 140 million yuan for the sales and promotion expenses of individual agents in 2018, and part of the invoice attached to the voucher was issued by a third-party company that has no substantial business dealings with the company
    .
    Shandong Buchang Pharmaceutical Co.
    , Ltd.
    paid 51,223,900 yuan to the pharmaceutical promotion company in the name of consulting fees and market promotion fees, and the pharmaceutical promotion company transferred the funds to the company's agents
    .
    The disastrously high sales expenses of pharmaceutical companies have contributed to the trend of high drug prices.
    The "checking books" of pharmaceutical companies began two years ago
    .
    With Kangmei Pharmaceuticals suspected of falsifying financial data, Buchang Pharmaceuticals and other leading pharmaceutical companies were frequently inquired by the Securities Regulatory Commission due to excessive sales costs as a signal, and a reorganization of the pharmaceutical industry from the finance and taxation department began
    .
    On June 4, 2019, the Ministry of Finance announced the launch of the 2019 pharmaceutical industry accounting information quality inspection work, involving 77 pharmaceutical companies
    .
    The Ministry of Finance emphasized that this inspection is a "penetrating" supervision of the pharmaceutical sales link, and will extend the inspection of affiliated companies and related sales, agency, advertising, consulting and other institutions, and will also inspect medical institutions when necessary
    .
    This means that inspections will center on these companies and radiate the entire pharmaceutical industry's production, circulation, and use links
    .
    According to the person in charge of the Ministry of Finance, due to the impact of the epidemic, the announcement of the results of administrative penalties has been postponed from last year to this year
    .
    This inspection of pharmaceutical companies was jointly completed by 14 regulatory bureaus and 31 financial departments (bureaus).
    This time, the pharmaceutical companies inspected by the relevant regulatory bureaus of the Ministry of Finance are disclosed
    .
    Punishments in other provinces are still in progress .
    Other violations of laws and regulations found in the inspection shall be transferred to the competent authority for handling
    .
    Experts pointed out that the joint inspection by the Ministry of Finance and the National Medical Insurance Administration is an action to help medical reform from the perspective of accounting information quality inspection, and to improve the satisfaction and sense of gain of the people.
    The inspection has a deterrent effect on the illegal behavior of pharmaceutical companies.
    Release the signal to strengthen financial supervision
    .
    In fact, the excessively high sales expenses and insufficient R&D investment of pharmaceutical companies have always been common problems in the industry, and the abnormally high sales expenses are also a "minefield" in the pharmaceutical industry
    .
    On May 12, 2019, Buchang Pharmaceutical accepted an inquiry from the Shanghai Stock Exchange for this
    .
    The annual report shows that in 2018, Buchang Pharmaceutical's sales expenses were 8.
    036 billion yuan, accounting for 59% of operating income, which was higher than the industry average
    .
    Among them, marketing, academic promotion and consulting fees are 7.
    486 billion yuan, accounting for more than 90%
    .
    According to the response, the marketing activity expenses accounted for nearly 40% of the sales expenses of Buchang Pharmaceutical
    .
    Some experts pointed out that no matter how beautiful a company's written financials are, there may be fraudulent statements.
    Some expenses are financially reasonable, but business considerations are unreasonable
    .
    This is the true cost of medicines
    .
    Due to the division of functions, those who understand auditing and finance may not know the business process of medicines, and "the medical insurance bureau understands medicines and the Ministry of Finance understands finances, and the combination of the two can better investigate the problems
    .
    " The cost of different types of pharmaceutical companies To get the bottom line is seen as a preparation for squeezing out the price of medicine
    .
    Zhu Xun, a professor at Jilin University, believes that this inspection can not only standardize the sales behavior of enterprises, but also promote the price reduction of medicines, tap the space for medical preservation, and reduce unreasonable expenses while clarifying the costs and profits of the enterprise
    .
    Cut off the chain of medical corruption and urgently need to systematically rectify the sales with money.
    On April 10, the website of the State Supervision Commission of the Central Commission for Discipline Inspection issued a message: Dai Longyong, the legal representative of Jiangxi Yongchang Pharmaceutical Co.
    , Ltd.
    , is suspected of bribery and is currently under supervision and investigation by the Jiangxi Provincial Supervision Commission.
    Retention measures have been taken
    .
    On March 23, the website of the Yunnan Provincial Commission for Discipline Inspection released a message: Yang Shoujun, the original legal representative of Kunming Tianxin Pharmaceutical Co.
    , Ltd.
    , and He Yan, director of the marketing department of Yunnan Pharmaceutical Co.
    , Ltd.
    , were involved in cardiovascular disease in Fuwai, Yunnan Province.
    hospital, former vice president of Malin Kun case of serious violation of law, has been retained
    .
    It is not uncommon for the pharmaceutical industry to be involved in bribery cases
    .
    For a long time, the interests of drug sellers and individual hospital leaders and medical staff have been deeply involved.
    Focusing on sales and neglecting R&D has become a chronic problem for many pharmaceutical companies
    .
    In 2020, a well-known pharmaceutical company in Southwest China will have sales expenses of 3.
    795 billion yuan and R&D expenses of only 181 million yuan
    .
    This time the Ministry of Finance notified the results of the inspection, and "sales with gold" became a key word
    .
    Statistics show that about 80% of our medicines are sold through hospital channels
    .
    A small piece of medicine, from the manufacturer to the patient, needs to go through many stages of drug procurement in public hospitals.
    The fees paid by the pharmaceutical companies to the bidding agency, hospital heads, medical representatives, doctors, etc.
    , will eventually be superimposed on the price of the medicine.
    On
    .
    Whether it is excessive sales expenses, or data fraud on costs and revenues, behind it all point to the gold sales model of the pharmaceutical industry
    .
    These intermediate costs are passed on to the price of medicines, which is the "direct driver" of the falsely high prices of medicines, and it is the national medical insurance funds and patients who will ultimately suffer losses
    .
    Investigating the deep-seated reasons, experts said: “On the one hand, it is the supply side.
    The homogeneity competition in the pharmaceutical industry is too serious.
    If you want to expand sales, you can only start with marketing.
    The fastest way is to give rebates
    .
    On the other hand, it is the user side.
    , The punishment for doctors’ kickbacks is still not severe enough, and the income structure is also a problem
    .
    ” According to estimates by the China Pharmaceutical Enterprise Management Association, the current number of medical representatives in China is about one million
    .
    Drugs involve the lives, health and safety of the people.
    As a link between doctors, hospitals and pharmaceutical factories, medical representatives are necessary and necessary to supervise their professional behaviors
    .
    If it is allowed to use all kinds of improper means to obtain hospital "tickets" for medicines, it will inevitably go against the original intention of the establishment of this profession
    .
    In order to obtain generous "targeted" rebates, some medical staff who cannot resist the temptation are likely to resort to methods that are contrary to medical ethics, such as prescribing more medicines, prescribing expensive medicines, and prescribing designated medicines
    .
    "The rebate is something under the table, but it may have an impact on what is on the table
    .
    "Cutting the chain of medical corruption and curbing the unreasonable and rapid growth of medical expenses is the top priority at the moment
    .
    The price of medicine and the credit evaluation system for recruitment and procurement are bright swords, and the first case of serious dishonesty involving drugs was suspended for online trading April 12 , Zhejiang Pharmaceutical Equipment Procurement Center issued a notice on the evaluation results of medical prices and untrustworthy levels of recruitment and procurement, disclosing a large amount of commercial bribery in the Lugua Polypeptide Injection of a listed pharmaceutical company, and rated the company’s untrustworthy level as "serious".
    And suspend online transactions in the province
    .
    As the country’s first governance case with a credit rating of “serious”, this marks the beginning of a substantial effect of the credit rating system
    .
    It is reported that Zhejiang province has also followed the procedures for other pharmaceutical companies that have rebate problems.
    Credit evaluations have been carried out, and some pharmaceutical companies have taken measures such as active price reductions to restore credit
    .
    In response to the recently exposed problems of pharmaceutical companies such as excessively high sales expenses and false expenses, which are contrary to integrity management and fair pricing, the National Medical Insurance Bureau will continue to Study and improve the credit evaluation system, strengthen the deterrent effect, and promote pharmaceutical companies to set prices in accordance with the principles of fairness, reasonableness, honesty and credibility, and consistent quality and price, and resolutely safeguard the interests of the people
    .
    The penalties showed that 19 companies were punished with 30,000 to 50,000 yuan Administrative penalty
    .
    Although the amount involved is as high as over 100 million, the current law has a maximum penalty of 50,000 yuan
    .
    The lower penalty standard is a dilemma faced by the Ministry of Finance for law enforcement, and the accounting law is currently being revised to this end
    .
    The National Medical Insurance Bureau also Facing the same dilemma
    .
    The relevant person in charge of the Price Recruitment Department of the National Medical Insurance Administration stated that pharmaceutical companies are often not sensitive to the fines of rebate cases
    .
    For this reason, the National Medical Insurance Administration has established a medical price and recruitment credit evaluation system for companies with serious circumstances.
    Will lose the opportunity to enter the centralized procurement market, which will have a powerful deterrent effect
    .
    "The first three batches of 112 drugs purchased in volume will be reduced by an average of 54%.
    The next step is to promote the purchase of consumables and Chinese patent medicines.
    Large-scale medical equipment will also be used in the future.
    Will consider including
    .
    "A few days ago, Yang Zhiguang, deputy director of the Department of System Reform of the National Health and Medical Commission, introduced the direction for the advancement of mass procurement of
    medicines.
    Pharmaceutical bidding and procurement has a history of nearly 20 years in China, but there are some drawbacks in the past bidding procurement
    .
    National Medical Insurance Administration Pharmaceuticals Zhang Ming, the head of the expert group of the Price and Bidding Purchasing Guidance Center, believes that the first is the decoupling of volume and price, and the price is generally only recruited without the volume, and the price of medicines is difficult to significantly decrease
    .
    The second is the uneven quality and the low concentration of pharmaceutical manufacturers.
    The sales cost is large, the R&D investment is not much, and the quality of generic drugs is uneven
    .
    The third is insufficient competition, the procurement level is low, the power is scattered, and the bargaining ability is insufficient
    .
    The fourth is the lack of coordination, the connection of various aspects is not in place, and the ex-factory price of the drug is high.
    There are many false highs in the final price of entering the hospital
    .
    Zhang Ming said that volume purchases can play a role in the market, purify the circulation environment, and promote the return of drug prices to a reasonable range
    .
    "The effect of price reduction can be said to be very significant, saving 670 drug costs every year.
    100 million yuan, plus local and other large-scale parts, it is predicted that more than 100 billion yuan will be saved each year
    .
    "By the end of 2020, the actual procurement volume of centralized drug procurement has reached 2.
    4 times the agreed procurement volume, which not only reduces the burden on the masses, but also helps guide companies to transform marketing models and promote the high-quality development of the pharmaceutical industry
    .
    Shanghai Food and Drug Safety Research Association Chairman Tang Minhao pointed out that the future market will definitely be a big wave, and those pharmaceutical companies that are not compliant, have no sense of innovation, or even rely on red envelopes to open up the market will be eliminated
    .
    Promote the integration, coordination, coordination, and resolute rectification of financial and accounting supervision and disciplinary inspection and supervision.
    For the first time, the Fourth Plenary Session of the 19th Central Commission for Discipline Inspection of the Pharmaceutical Industry included financial and accounting supervision, audit supervision, and statistical supervision into the party and state supervision system, and proposed to improve the party and state supervision system
    .
    It is necessary to take internal supervision as the leading factor and promote the people’s congress.
    Supervision, democratic supervision, administrative supervision, judicial supervision, audit supervision, financial and accounting supervision, statistical supervision, mass supervision, and public opinion supervision are organically integrated and coordinated
    .
    The Fifth Plenary Session of the 19th Central Commission for Discipline Inspection pointed out that to give full play to the political leadership role of internal party supervision, and integrate supervision into regional governance, departmental governance, industry governance, grassroots governance, and unit governance
    .
    Economic activities produce accounting information, which reflects and records all economic activities
    .
    Strict financial and accounting supervision is not only a necessary condition for the scientific governance of micro-units, but also a necessary means to strengthen national governance and maintain financial order
    .
    "History and reality show that financial and accounting supervision is indispensable.
    Doing a good job in financial and accounting supervision is not only an objective need to improve the party and state supervision system, and to improve the modernization of the national governance system and governance capabilities, but also to establish a fully standardized, transparent, scientifically standardized, and well-constrained budget.
    The system guarantees the party’s internal requirements for the implementation of financial work policies and decision-making arrangements
    .
    ” said Wang Zhendong, Secretary of the Party Leadership Group and Director of the Shandong Supervision Bureau of the Ministry of Finance
    .
    As an important part of the party and state's supervision system, financial and accounting supervision is its due responsibility to prevent and expose corruption and enhance the "immunity" of the country's governance system
    .
    For clues of disciplinary violations discovered in financial supervision, timely transfer to the discipline inspection and supervision organs for handling, and cooperation with the discipline inspection and supervision organs to carry out financial supervision and accountability is the proper meaning of the financial supervision to strengthen cooperation with discipline inspection and supervision
    .
    According to Zhang Xueping, member of the Party Leadership Group, Disciplinary Inspection Team Leader, and Deputy Director of the Ningxia Supervision Bureau of the Ministry of Finance, the role of financial and accounting supervision in strengthening the construction of party >
    .
    "Past supervision practices show that financial and accounting supervision finds and transfers a large number of clues to cases every year, which has become an important force in the fight against corruption. .
    "We will continue to strengthen cooperation with the National Medical Insurance Administration, earnestly perform the responsibility of financial and accounting supervision, adhere to'strong penetration, plug loopholes, use heavy codes, and positive trends', increase law enforcement inspections, effectively improve the quality of accounting and auditing, and protect the interests of the people.
    And implementation of major reforms
    .
    "The relevant person in charge of the Ministry of Finance said
    .
    (Our reporter Guan Xiaopu)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.